Shares of Galectin Therapeutics Inc. were down nearly 50% in extended trading on Tuesday as its phase IIa trial of GR-MD-02 in nonalcoholic steatohepatitis patients with advanced fibrosis failed to meet the study goals.
from RTT - Biotech http://ift.tt/2cAynb3
via IFTTT
No comments:
Post a Comment